Compares ILB with riluzole in people with amyotrophic lateral sclerosis
Tests ILB against riluzole in adults with amyotrophic lateral sclerosis, a nerve disease.
Key facts
- Who runs it
- Oslo University Hospital HF
- Where
- Bergen, Bodo, Brumunddal, Drammen, Graalum, Kristiansand S, Loerenskog, Molde, Oslo, Skien, Stavanger, Toensberg, Tromsoe, and Trondheim, NorwaySee the 14 sites
- Trial code
- Registry title
- A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in participants with Amyotrophic Lateral Sclerosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 116 people, planned
- Started
- 16 Feb 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 24 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with ALS (amyotrophic lateral sclerosis) in stable health, whose symptoms began within the last 24 months and who already take riluzole.
- Age
- 18 to 80 years
- Sex
- Men and women can join.
- Disease stage
- ALS diagnosed by the revised Gold Coast criteria. Symptoms began 24 months ago or less. Disease progression rate ∆FRS of 0.4 or more. FVC of 60 % or more of the predicted value. ALSFRS-R score of at least 28 points.
- Earlier treatment
- Must have started riluzole (100 mg/day) at least 2 weeks before screening and be willing to pause it 48 hours before Day 1. Cannot have taken warfarin or direct oral anticoagulants (DOACs) in the 14 days before screening.
Main reasons for not taking part
- Dementia, other brain or nerve diseases, or other serious uncontrolled disease that could affect the trial
- Pregnant or nursing
- Alcohol, drug or medication abuse in the 12 months before screening
- Known allergy to dextran sulfate, riluzole or other ingredients of the trial medicines
- Clinically significant abnormal blood clotting results at screening
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age 18 to 80 years inclusive at the time of signing the informed consent
- Must be in a stable health condition as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring at screening
- Male or female diagnosed with ALS according to the World Federation of Neurology revised Gold Coast criteria
- Onset of ALS symptoms ≤ 24 months at screening visit
- Disease progression rate ∆FRS ≥ 0.4 at screening
- FVC ≥ 60 % (Forced Vital Capacity) of predicted valued for gender, height, and age at screening
- Must have started treatment of Riluzole (100 mg/day) at least 2 weeks prior to screening and willing to pause Riluzole 48 hours prior to the baseline visit (Day 1)
- ALSFRS-R score of at least 28 points at screening
Who cannot take part
- A participant with a history (within 12 months before screening) of current alcohol, drug, or medication abuse, as assessed by the investigator. Alcohol abuse is defined as consuming more than 14 units per week
- Participants receiving active treatment with drugs warfarin and direct oral anticoagulants (DOACs) 14 days prior to screening visit
- A participant with dementia, other neurodegenerative diseases (e.g. Parkinson disease, multiple sclerosis) or any significant uncontrolled neurological, psychiatric, neoplastic, systemic, or organic disease (e.g. significant renal, hepatic or pulmonary disorder with on-going treatment not attributed to ALS) that, in the opinion of the investigator or medical monitor, could interfere with the conduct of the trial or affect its results
- A participant with known allergy or intolerability to dextran sulfate, riluzole, and other ingredients of the IMPs
- A participant having clinically significant abnormal coagulation parameters: prothrombin complex-international normalized ratio (INR) > 1.5, fibrinogen <1.5 g/L, von Willebrand factor deficit and APTT > 41 seconds at screening
- A participant who is pregnant or nursing
Where in Norway
- Helse Bergen HFBergen, NorwayTaking people
- Nordlandssykehuset HFBodo, NorwayTaking people
- Sykehuset Innlandet HFBrumunddal, NorwayTaking people
- Vestre Viken HFDrammen, NorwayTaking people
- Sykehuset Oestfold HF KalnesGraalum, NorwayTaking people
- Sorlandet Sykehus HFKristiansand S, NorwayTaking people
- Akershus University HospitalLoerenskog, NorwayTaking people
- Helse Moere Og Romsdal HFMolde, NorwayTaking people
- Oslo University Hospital HFOslo, NorwayTaking people
- Sykehuset Telemark HFSkien, NorwayTaking people
- Helse Stavanger HFStavanger, NorwayTaking people
- Sykehuset I Vestfold HFToensberg, NorwayTaking people
- Universitetssykehuset Nord-Norge HFTromsoe, NorwayTaking people
- St. Olavs hospital HFTrondheim, NorwayTaking people
About the trial
What the trial wants to find out
To evaluate the efficacy of ILB® compared to Riluzole in reducing disease progression in participants with amyotrophic lateral sclerosis (ALS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in participants with Amyotrophic Lateral Sclerosis
- Plain-language title
- Compares ILB with riluzole in people with amyotrophic lateral sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 24 June 2026